The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab

Targeting of immunoglobulin E (IgE) represents an interesting approach for the treatment of allergic disorders. A high-affinity monoclonal anti-IgE antibody, ligelizumab, has recently been developed to overcome some of the limitations associated with the clinical use of the therapeutic anti-IgE anti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nat Commun
Hlavní autoři: Gasser, Pascal, Tarchevskaya, Svetlana S., Guntern, Pascal, Brigger, Daniel, Ruppli, Rahel, Zbären, Noemi, Kleinboelting, Silke, Heusser, Christoph, Jardetzky, Theodore S., Eggel, Alexander
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6949303/
https://ncbi.nlm.nih.gov/pubmed/31913280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-13815-w
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky